Immunotherapy for metastatic colorectal cancer: present status and new options (Q37972934)

26 August 2017

title

Immunotherapy for metastatic colorectal cancer: present status and new options (English)

1 reference

26 August 2017

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

3

Inge Marie Svane

1 reference

26 August 2017

2

Mads Hald Andersen

1 reference

26 August 2017

4

Per Thor Straten

1 reference

26 August 2017

Eva Ellebaek

1

1 reference

26 August 2017

publication date

3 January 2012

1 reference

Scandinavian Journal of Gastroenterology

26 August 2017

published in

1 reference

26 August 2017

volume

47

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

315-324

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Immunogenicity of constitutively active V599EBRaf

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Desirable cell death during anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon c

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640831

10.3109/00365521.2012.640831

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference